Toronto, Ontario--(Newsfile Corp. - January 9, 2025) - Alberto Morales, Executive Chairman and Chief Executive Officer, Andean Precious Metals Corp. ("Andean Precious Metals" or the "Company") (TSX: APM), and his team joined Dean McPherson, Head, Business Development, Global Mining, Toronto Stock Exchange (TSX), to open the market to celebrate the Company's graduation to Toronto Stock Exchange.Cannot view this video? Visit:https://www.youtube.com/watch?v=U22wnmTOqTEAndean is a growing precious metals produ ...

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at an offering ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Exhibit 99.1 Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Apt ...

Clinical-stage biopharmaceutical firm Aptorum (NASDAQ:APM) is seeing its market value rise dramatically today on a merger between its wholly owned subsidiary and an artificial intelligence (AI) and automation platform. A combination of AI enthusiasm and some support from institutional investors is likely what’s helping APM stock rocket higher.Per MarketWatch, Aptorum has agreed to merge with YOOV Group, which specializes in leveraging advanced AI techniques to optimize business operations. Specifically, the ...

Aptorum (NASDAQ:APM) stock is rocketing higher on Wednesday after the biopharmaceutical company announced a merger agreement with YOOV Group.This will be a reverse merger that will see YOOV shareholders hold 90% of the combined company after the deal is complete. The remaining 10% will belong to current APM stockholders.To go along with this merger, Aptorum majority investor Jurchen Investment and wholly-owned subsidiary Aptorum Therapeutics Limited will take part in a split. That will see this legacy busin ...

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the “Board”), respectively. If the Merger Agreement is approved by Aptorum’s and Y ...

Exhibit 99.1 Financial Statements Table of Contents | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022 | F-2 | | Condensed Consolidated Statements of Operations and Comprehensive Loss for the six months ended June 30, 2023 and | | | 2022 (Unaudited) | F-3 | | Condensed Consolidated State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Exhibit 99.1 Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update New York & London & Paris, April 28, 2023 – Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided an update on clinical and corporate dev ...